Rubrik's CEO let 800 employees sit in on board meetings — and he says it supercharged the company
For the first seven to eight years of building the company, Rubrik's CEO opened board meetings to all staff.
Bipul Sinha said as many as 800 staff members tuned in to these meetings.
The data management firm went public in April 2024 and is worth $19 billion.
But for the first seven to eight years of building the data management firm Rubrik, Bipul Sinha let every employee in.
"We put the board meeting in a large conference room," the CEO and cofounder said on an episode of "The Logan Bartlett Show" published Friday. "We let people sit on the ground if needed."
"People could ask questions, so it was not a webinar style," Sinha said. "We've had situations where people actually asked hard questions in the middle of the board meeting."
As many as 800 staff members tuned in to some ofthese sessions, Sinha said.
"It is a direct result of this idea of transparency that really created alignment and velocity," the former venture partner at Lightspeed said.
"Everybody knew where we are going and what needed to be done," he added.
Sinha cofounded Rubrik in 2014. The company went public in April last year and is worth $19 billion.
The meetings, Sinha said, were his way of showing there were "no sacred cows" and "no information control."
"Everybody can demand answers, and when people demand answers, then people also become very responsible, they take it very personally," he said.
The format wasn't without friction. Some VCs and executives were initially skeptical, Sinha said.
"It was a little non-intuitive for them initially," Sinha said. "Sometimes you don't realize how many people are on the call, and we would have discussions about an individual," he added.
Eventually, Rubrik had to close the meetings to employees "because of the IPO and other activity," Sinha said.
Sinha did not respond to a request for comment from Business Insider.
Rubrik isn't the only company that has pushed for more transparency in high-stakes meetings.
At Blackstone, senior leaders make it a point to involve junior staff during the private equity firm's deal meetings.
"We'll go around in many of these committees and ask the most junior people in the room, 'hey, what do you think?'" Blackstone President Jon Gray said earlier this year. "We want them to articulate why they have conviction."

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
Hologic Climbs 13% in a Month: How Should You Play the Stock?
After lagging for months, Hologic HOLX has picked up momentum in recent weeks. Shares of the Marlborough, MA-based company have climbed 13.3% over the past month, higher than the industry and the broader Medical sector's gains of 2.4% and 3.4%, respectively. The current price is now 23.9% above the 52-week low of $51.90, boosted in part by reports that Hologic declined a private takeover bid from TPG and Blackstone. HOLX has also managed to outperform two of its key competitors — Exact Sciences EXAS and Becton, Dickinson and Company BDX, or BD, in the same time frame. Image Source: Zacks Investment Research Investor sentiment was already subdued after the release of the company's fiscal 2025 second-quarter earnings in early May. Hologic met adjusted EPS expectations with a modest revenue beat but revised its annual outlook due to the growing tariff impact from China and Costa Rica, funding cuts affecting the Africa business, and a soft capital equipment market. In contrast, Exact Sciences anticipates 'little to no tariff impact' due to all domestic operations, while BD expects $90 million in tariff expenses for fiscal 2025, mostly from China imports. That said, let's explore what might be driving Hologic's recent rally. On May 27, HOLX shares rose nearly 15% following a report from the Financial Times that the company turned down a non-binding offer from private equity (PE) firms TPG and Blackstone. The deal was valued at up to $16.7 billion, including debt. These firms, known for their solid history of healthcare investments, teamed up last year to explore a potential acquisition of Bausch + Lomb, which eventually did not happen. The proposed takeover bid of Hologic would have been one of the largest leveraged buyouts of the year, valuing the company's shares between $70 and $72 — roughly a 30% premium to the May 23 closing price of $54.28. The report also stated that there is a possibility the deal discussions might resume, according to people with knowledge of the matter. Hologic has attracted buyers' attention for a while now. Of late, the take-private activities by PE firms have seen a sharp increase, such as Sycamore Partners' $24 billion deal for Walgreens Boots Alliance, Thoma Bravo's $10.6 billion acquisition of Boeing's software unit, and 3G Capital's $10.5 billion deal for Skechers. Nonetheless, the high premium in the offer signals strong confidence in Hologic's growth potential. The company presented new data showing the significant clinical impact of the Breast Cancer Index ('BCI') test at the 2025 American Society of Clinical Oncology Annual Meeting held on June 2. The molecular, gene expression-based test from Hologic's subsidiary, Biotheranostics, has been a key growth driver in the molecular diagnostics business over the past few quarters. The latest data from the prospective, multi-center BCI Registry Study highlights how this genomic test plays a critical role in guiding extended endocrine therapy decisions for women with early-stage, hormone receptor-positive (HR+) breast cancer. With more than 2,800 patients involved, the study found that BCI testing led to a change in treatment recommendations for about four in 10 cases. Additionally, physicians' confidence in their treatment recommendations got a boost, while patients felt comfortable in their decisions, citing fewer concerns about cost, drug safety and preference related to extended endocrine therapy benefits. Hologic looks attractive from a valuation standpoint. The stock has been trading at a price-to-sales (P/S) of 3.40X over the past five years compared to its median of 4.33X and the industry average of 4.16X. It has a Value Score of B at present. Image Source: Zacks Investment Research Meanwhile, both Exact Sciences and BD are trading at a premium to their industry average, with P/S of 3.16X and 2.20X respectively. Molecular Diagnostics assays are likely to continue to be the principal revenue-generating component in the Diagnostics division. As Hologic drives awareness and reimbursement in the highly unpenetrated U.S. vaginitis market, the BV CV/TV assay is poised to see a strong uptake. Aligning with its long-term revenue diversification strategy, the company's Breast Health service revenues are now larger and growing more steadily than the gantry business. The 2024 acquisition of Endomagnetics boosted the Interventional Breast portfolio with market-leading product lines and strong R&D capabilities for further portfolio expansion. The upcoming launch of innovations like the Envision Mammography Platform is likely to gain a favorable reception. In Surgical, Myosure's strong international growth points to the high demand for minimally invasive options for treating uterine polyps and fibroids. Hologic continues to expand this division both organically and through acquisitions such as Gynsesonics, leveraging its established sales channel. Further, the company is building capabilities to grow internationally on a consistent basis by going directly into more geographies and businesses. A consistently strong profitability has contributed to a fortress balance sheet over time, allowing Hologic to execute on both tuck-in M&A and share repurchases. Based on short-term price targets offered by 15 analysts, the Zacks average price target is $68.13 per share. The average suggests a potential 8.02% upside from last Friday's closing price. Image Source: Zacks Investment Research Hologic has some promising catalysts for long-term expansion, supported by an attractive valuation relative to its industry. However, despite outperforming peers over the past month, the Zacks Rank #3 (Hold) stock is navigating a turbulent macroeconomic landscape, which is expected to weigh on its financial performance in the near term. Hence, those eyeing HOLX may find it wise to wait for a better entry point, while current shareholders should retain their position. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Becton, Dickinson and Company (BDX) : Free Stock Analysis Report Hologic, Inc. (HOLX) : Free Stock Analysis Report Exact Sciences Corporation (EXAS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
8 hours ago
- Yahoo
Rubrik, Inc. (RBRK): A Bull Case Theory
We came across a bullish thesis on Rubrik, Inc. (RBRK) on Deep Value Returns' Substack. In this article, we will summarize the bulls' thesis on RBRK. Rubrik, Inc. (RBRK)'s share was trading at $98.54 as of 4th June. A high-rise office building, its staff busy at work providing cybersecurity services. Rubrik (RBRK) has significantly outpaced expectations, approaching the author's $110 per share target well ahead of the original summer 2026 timeline. While this rapid rally increases the likelihood of a near-term pullback, particularly around earnings as investors look to lock in profits, the recommendation remains to hold the position. The stock's earlier volatility and sharp rebounds underscore the importance of avoiding stop-loss strategies, which might have shaken out long-term investors prematurely. Rubrik's core strength lies in its comprehensive 'cyber resilience' platform, which goes beyond traditional cybersecurity by ensuring companies can quickly recover from attacks. Its unified approach protects data across cloud, on-premises, and popular SaaS applications like Microsoft 365, offering a critical solution as businesses face growing AI-driven data risks. The company's fiscal 2026 guidance, given amid macro uncertainty and market volatility in March, was understandably conservative. Nevertheless, if Rubrik can achieve 45% year-over-year growth, it would significantly bolster confidence in its trajectory toward the $110 target. Although the stock trades at a rich 160x forward free cash flow, the valuation reflects optimism around Rubrik's scalable model. Management delivered an exceptional 29% free cash flow margin in Q4 FY25, but full-year expectations have been tempered to 10%, implying some lumpiness ahead. Still, with a projected free cash flow of $120 million and powerful demand trends in cybersecurity, Rubrik is positioned to grow into its valuation. Despite short-term risks, the structural growth story remains intact, and investors are encouraged to stay patient as the company continues to execute within a high-potential sector. We previously covered a on Rubrik (RBRK) by ElectSamsepi0l on the wallstreetbets Subreddit in December 2024, highlighting its post-IPO momentum, partnerships, and strong ARR growth crossing $1B. The thesis has played out well as the stock price of RBRK has appreciated by roughly 84% since then. Deep Value Returns' June 2025 Substack echoes this optimism but emphasizes Rubrik's accelerating path toward a $110 price target, robust free cash flow margins, and its differentiated cyber resilience platform, framing it as a long-term compounder despite elevated valuation multiples. Rubrik, Inc. (RBRK) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 45 hedge fund portfolios held RBRK at the end of the first quarter which was 41 in the previous quarter. While we acknowledge the risk and potential of RBRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey.
Yahoo
8 hours ago
- Yahoo
Rubrik, Inc. (RBRK): A Bull Case Theory
We came across a bullish thesis on Rubrik, Inc. (RBRK) on Deep Value Returns' Substack. In this article, we will summarize the bulls' thesis on RBRK. Rubrik, Inc. (RBRK)'s share was trading at $98.54 as of 4th June. A high-rise office building, its staff busy at work providing cybersecurity services. Rubrik (RBRK) has significantly outpaced expectations, approaching the author's $110 per share target well ahead of the original summer 2026 timeline. While this rapid rally increases the likelihood of a near-term pullback, particularly around earnings as investors look to lock in profits, the recommendation remains to hold the position. The stock's earlier volatility and sharp rebounds underscore the importance of avoiding stop-loss strategies, which might have shaken out long-term investors prematurely. Rubrik's core strength lies in its comprehensive 'cyber resilience' platform, which goes beyond traditional cybersecurity by ensuring companies can quickly recover from attacks. Its unified approach protects data across cloud, on-premises, and popular SaaS applications like Microsoft 365, offering a critical solution as businesses face growing AI-driven data risks. The company's fiscal 2026 guidance, given amid macro uncertainty and market volatility in March, was understandably conservative. Nevertheless, if Rubrik can achieve 45% year-over-year growth, it would significantly bolster confidence in its trajectory toward the $110 target. Although the stock trades at a rich 160x forward free cash flow, the valuation reflects optimism around Rubrik's scalable model. Management delivered an exceptional 29% free cash flow margin in Q4 FY25, but full-year expectations have been tempered to 10%, implying some lumpiness ahead. Still, with a projected free cash flow of $120 million and powerful demand trends in cybersecurity, Rubrik is positioned to grow into its valuation. Despite short-term risks, the structural growth story remains intact, and investors are encouraged to stay patient as the company continues to execute within a high-potential sector. We previously covered a on Rubrik (RBRK) by ElectSamsepi0l on the wallstreetbets Subreddit in December 2024, highlighting its post-IPO momentum, partnerships, and strong ARR growth crossing $1B. The thesis has played out well as the stock price of RBRK has appreciated by roughly 84% since then. Deep Value Returns' June 2025 Substack echoes this optimism but emphasizes Rubrik's accelerating path toward a $110 price target, robust free cash flow margins, and its differentiated cyber resilience platform, framing it as a long-term compounder despite elevated valuation multiples. Rubrik, Inc. (RBRK) is not on our list of the 30 Most Popular Stocks Among Hedge Funds. As per our database, 45 hedge fund portfolios held RBRK at the end of the first quarter which was 41 in the previous quarter. While we acknowledge the risk and potential of RBRK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 8 Best Wide Moat Stocks to Buy Now and 30 Most Important AI Stocks According to BlackRock. Disclosure: None. This article was originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data